Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
Freenome (FRNM) plans to report its third-quarter 2026 financial results after the market close on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Freenome (FRNM) plans to report its third-quarter 2026 financial results after the market close on November 10, 2026. The results cover the quarter ended September 30, 2026. A conference call will follow at 1:30 pm Pacific Time / 4:30 pm Eastern Time, with a live and archived webcast available on the company’s investor relations website.
Key Figures
- Scheduled results release
- November 10, 2026
- Third-quarter 2026 financial results, after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Following the release, Freenome will host a conference call to discuss its financial results at 1:30 pm Pacific Time / 4:30 pm Eastern Time.
To participate in the conference call, please register here before the start of the call. A live and archived webcast will be available on the “Events” page of Freenome’s investor relations website at https://investors.freenome.com/.
About Freenome
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Media contact
Ryan Flinn
The Grace Group
ryan@gracegroup.us
Investor Contact
Gilmartin Group LLC
investor-relations@freenome.com
